What is your current role on AMYPAD?
I am a Global Trial Leader, GTL, at Janssen and I am assisting Ifrah Iidow and Isadora Alves Lopes with operational aspects of the AMYPAD Prognostic Natural History Study (PNHS). I am here to provide support to the Sponsor, VUmc, in any way possible to help make the operations of the study run smoothly. I have been working in the clinical field for the last 13 years with the last 7 years as a GTL and prior to that I worked in the pre-clinical filed for 9 years.

What is your overall vision?
My overall vision for the AMYPAD PNHS study is the same as everyone that works on the study, from internal teams to study sites, and that is for the study to be successful and fruitful. This begins with my assistance to the Sponsor to help complete site activation the enrollment of the 2,000 volunteers, then wait to see how their imaging data will be able to help better understand the natural course of Alzheimer’s disease.

What do you find most challenging about the project?
The most challenging aspect of the AMYPAD PNHS project is getting all the sites active with all required approvals and the complexities involved with PET tracer manufactures and scheduling of PET scans at the various study sites.